powered by centersite dot net
Medications
Resources
Basic InformationLatest News
New Cholesterol Drugs Vastly Overpriced, Study ContendsFDA May Limit 'Risk Info' in Direct-to-Consumer TV Drug AdsHealth Tip: Throwing Out Leftover MedicineFDA Announces Recall of Some Liquid Pharmaceutical ProductsIs FDA Taking Close Enough Look at Fast-Tracked Drugs?U.S. Antidepressant Use Jumps 65 Percent in 15 YearsThe Fine Print on Medication Expiration DatesAmericans Taking More Prescription Drugs Than Ever: SurveyInappropriate Med Use High in Cognitively Impaired SeniorsA Reminder That Meds and Grapefruit Don't Always MixAspirin Responsiveness Can Change After Bariatric SurgerySome Medicines Boost Sensitivity to SunPainkiller Prescriptions More Prone to Errors If HandwrittenMedication Mistakes Have Doubled in U.S. Since 2000: StudyMarket Competition Linked to Change in Generic Drug PricesIs Your Child's 'Penicillin Allergy' Real?FDA Seeks to Increase Number of Generic Drugs on MarketWhen Is an Opioid Safe to Take?Lifesaving Drugs From Pfizer in Short Supply: FDALeading U.S. Doctors' Group Takes Aim at Rising Drug PricesU.S. Hospitals Still Prescribe Too Many Antibiotics: StudyBirth Control Pills Recalled Due to Danger of Unintended PregnancyNew Drugs Show Promise as First to Prevent MigraineMedication Adherence Up With Refill Synchronization ModelModified Vancomycin May Help Fight Bacterial ResistanceScientists Tweak Antibiotic to Boost Power Against 'Superbugs'New Cholesterol Fighting Meds Target Key GeneResearchers Say PDE5 Inhibitors Don't Cause MelanomaNearly a Third of Drugs Hit by Safety Issues After FDA ApprovalU.S. Moves to Avert Shortage of Yellow Fever VaccineOpioid Use by Iraq, Afghanistan War Vets Mirrors Rest of U.S.: StudyApril 29 Is National Prescription Drug Take Back DayERs Administering More Medications IntranasallyFDA Warns Against Children Taking Codeine, TramadolPhysicians Finding Ways to Work Around Cost of Rx MedicationsRuling Out Penicillin Allergy by Testing Inpatients Saves MoneyEpiPen Out-of-Pocket Costs More Than Doubled Over DecadeAACR: Regular Aspirin Use Linked to Lower Cancer MortalityFDA Approves Noctiva Nasal Spray for Nocturnal PolyuriaFDA Approves Odactra for House Dust Mite AllergiesHow Much Melatonin Is Really in That Supplement?Antidepressant Efficacy Varies for Depressive Symptom ClustersDo You Need an Antibiotic?'Off-Label' Antidepressants Common, But Where's the Evidence?Docs More Likely to Prescribe Antibiotics If Patients Expect ThemSimilar Adverse Event Risk for Typical, Atypical AntipsychoticsRx Adherence Reminders No More Effective at 'Fresh Start' DatesThink You're Allergic to Penicillin? Check AgainExcessive FDA Regulation Driving High Drug PricesOutcomes-Based Pricing Suggested for New, Costly Drugs
Questions and AnswersVideosLinksBook Reviews
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Mental Disorders
Mental Health Professions

Excessive FDA Regulation Driving High Drug Prices


HealthDay News
Updated: Jan 11th 2017

new article illustration

WEDNESDAY, Jan. 11, 2017 (HealthDay News) -- The excessive regulatory regime at the U.S. Food and Drug Administration is an important driver of high drug prices, and should be curbed to introduce more competition and lower prices, according to a report published online Jan. 5 by the National Center for Policy Analysis.

In the report, Devon Herrick, from the National Center for Policy Analysis discusses rising drug costs and ways to reduce the costs of drugs.

Herrick notes that the excessive regulatory regimen at the FDA is an important driver of high drug prices, and that a more rational path to drug approval is needed to boost competition and contain drug prices. The FDA has fast-tracked approval of new, first-in-class drugs while follow-on drugs can take up to 15 years to research, develop, and obtain approval due to regulatory barriers. Introducing drug competition can reduce prices considerably: The average generic price is halved when there are two competing generics in a drug class. In response to increased public scrutiny in relation to the high prices of drugs in 2016, drug companies blamed the "middleman," which is actually the industry supply chain, from drug makers, wholesalers, and pharmacies, through drug benefit plans.

"A way to rein-in high drug prices is to inject more competition," Herrick writes. "Newer drugs would face numerous competitors if it didn't require years and cost $1 billion or more to bring a new product to market."

Full Text